| Marcella Katsnelson, DO | |
|
30 Prospect Ave, Hackensack, NJ 07601-1915 | |
| (551) 996-1548 | |
| Not Available |
| Full Name | Marcella Katsnelson |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 8 Years |
| Location | 30 Prospect Ave, Hackensack, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942663158 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Uc San Diego Health Hillcrest - Hillcrest Med Ctr | San diego, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of California | 3577476761 | 1692 |
News Archive
Scientists at the National Institutes of Health have developed a mouse model to study the sexual and fetal transmission of Zika virus. This will enable studies to further understanding of how the Zika virus spreads, thereby allowing treatments to be developed.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a collaboration agreement with Généthon (Evry, France) for the development and exploitation of lentivirus packaging cell lines based on CEVEC's proprietary CAP GT technology.
deCODE genetics (an Amgen subsidiary) and Illumina, global leaders in analyzing and understanding the human genome, together with scientists from the National Hospital of Iceland and the University of Iceland reported today in the journal Nature the identification of a rare nonsense mutation that confers high risk of osteoporosis and osteoporosis related traits.
Preschool children with tooth decay may be more likely to be overweight or obese than the general population and, regardless of weight, are more likely to consume too many calories, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.
Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).
› Verified 1 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376646869 PECOS PAC ID: 3577476761 Enrollment ID: O20031112000695 |
News Archive
Scientists at the National Institutes of Health have developed a mouse model to study the sexual and fetal transmission of Zika virus. This will enable studies to further understanding of how the Zika virus spreads, thereby allowing treatments to be developed.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a collaboration agreement with Généthon (Evry, France) for the development and exploitation of lentivirus packaging cell lines based on CEVEC's proprietary CAP GT technology.
deCODE genetics (an Amgen subsidiary) and Illumina, global leaders in analyzing and understanding the human genome, together with scientists from the National Hospital of Iceland and the University of Iceland reported today in the journal Nature the identification of a rare nonsense mutation that confers high risk of osteoporosis and osteoporosis related traits.
Preschool children with tooth decay may be more likely to be overweight or obese than the general population and, regardless of weight, are more likely to consume too many calories, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.
Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marcella Katsnelson, DO Po Box 232410, San Diego, CA 92193-2410 Ph: () - | Marcella Katsnelson, DO 30 Prospect Ave, Hackensack, NJ 07601-1915 Ph: (551) 996-1548 |
News Archive
Scientists at the National Institutes of Health have developed a mouse model to study the sexual and fetal transmission of Zika virus. This will enable studies to further understanding of how the Zika virus spreads, thereby allowing treatments to be developed.
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a collaboration agreement with Généthon (Evry, France) for the development and exploitation of lentivirus packaging cell lines based on CEVEC's proprietary CAP GT technology.
deCODE genetics (an Amgen subsidiary) and Illumina, global leaders in analyzing and understanding the human genome, together with scientists from the National Hospital of Iceland and the University of Iceland reported today in the journal Nature the identification of a rare nonsense mutation that confers high risk of osteoporosis and osteoporosis related traits.
Preschool children with tooth decay may be more likely to be overweight or obese than the general population and, regardless of weight, are more likely to consume too many calories, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.
Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).
› Verified 1 days ago
Shabaz Ahmed, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 551-996-4466 | |
Xuefen Xie, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 551-996-2000 | |
Mrs. Noha El Torgoman, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 551-996-2000 | |
Alan Chu, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 551-996-3500 | |
George F Katzenbach Iii, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 551-996-5430 | |
Miss Elizabeth Tam, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 551-996-2000 | |
Dr. Sureshbhai N Patel, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Faculty Practice, Hackensack, NJ 07601 Phone: 201-441-3349 |